Author

C. Garratt

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

ODM-209 showed activity in heavily pretreated participants with mCRPC, particularly those with activating AR-LBD mutations, with an expected AE profile.

A. Bernard-Tessier, I. Spanggaard, T. Utriainen et al. · European Journal of Cancer · 0 citations